CHEK1 and gastric cancer: It can be seen from these studies that Wee1, CHK1, PARP, and others are all valuable targets in the treatment of gastric cancer, and the combination of different target-related inhibitors may be a more effective strategy for the treatment of gastric cancer in the future, which improves the overall treatment outcome in patients with advanced gastric cancer.